Immunocon Bioremedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 1292.59%
About Immunocon Bioremedies
Immunocon Bioremedies Private Limited (IBPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 September 2011 and has a history of 13 years and five months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shakti Upadhyay, Pooja Parekh, and Sonali Parekh serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233MH2011PTC221624
-
Company No.
221624
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Sep 2011
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Immunocon Bioremedies?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shakti Upadhyay
|
Director | 07-Sep-2011 | Current |
|
Pooja Parekh
|
Director | 23-Sep-2013 | Current |
|
Sonali Parekh
|
Director | 23-Sep-2013 | Current |
Financial Performance of Immunocon Bioremedies.
Immunocon Bioremedies Private Limited, for the financial year ended 2016, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immunocon Bioremedies?
In 2017, Immunocon Bioremedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Trisamya Art & Design LlpShakti Upadhyay is a mutual person
-
Trisamya Wellness Llp
Shakti Upadhyay is a mutual person
-
Trisamya Foundation
Shakti Upadhyay is a mutual person
-
Trisamya Healthcare Private Limited
Shakti Upadhyay is a mutual person
-
Luna Hospitality Llp
Pooja Parekh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immunocon Bioremedies?
Immunocon Bioremedies has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immunocon Bioremedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunocon Bioremedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
